June 2022

活動性強直性脊椎炎患者におけるトファシチニブの疼痛, 倦怠 感, 健康関連QOLおよび労働生産性に関する効果: フェーズ3, 無作為化二重盲検プラセボ対照試験結果

RMD Open 2022 doi:10.1136/rmdopen-2022-002253

Navarro-Compán et al, determined the effectiveness of tofacitinib in patients with active ankylosing spondylitis in a Phase III, randomised, double-blind, placebo-controlled trial.

Keywords:

February 2022

関節リウマチ患者におけるトファシチニブの用量調節の有効 性と安全性に対する影響: オープンラベル長期延長試験の post hoc 解析 (ORAL Sequel)

Clin Rheumatol. 2022 Jan 1. Epub ahead of print doi: 10.1007/s10067-021-05908-z

Post-hoc analysis shows that dosing up from tofacitinib 5 to 10 mg BID is associated with improved efficacy for up to 12 months, versus staying on 5 mg BID, and dosing down from 10 to 5 mg BID is not generally associated with a significant loss of efficacy.Although clinical trials have generally shown no significant differences, in terms of efficacy and safety, when switching tofacitinib dose up or down, these per-protocol switches are not directly informative for clinical decision-making in dai...

Keywords:

January 2022

トファシチニブ治療中関節リウマチ患者の間質性肺疾患発生率

J Clin Rheumatol. 2021;27(8):e482–e490

This post hoc analysis of pooled data from 21 clinical trials in the tofacitinib clinical trial programme highlights the importance of identifying known risk factors of RA-interstitial lung disease (ILD) in clinical practice.Citera, et al. investigated incidence rates of ILD – an extra-articular manifestation of RA – in patients with RA, receiving tofacitinib 5 or 10 mg BID and sort to identify potential risk factors for ILD in these patients....

Keywords: